Alphatec (US:ATEC)2025-06-16 16:45Financial Performance & Outlook - Full year revenue reached $91.7 million in 2018 [7], falling short of the $92-$95 million guidance [7] - Strategic distribution revenue increased by 29% from FY2017 to FY2018, reaching $66.3 million [53] - Legacy and terminated distribution revenue decreased by 51% from FY2017 to FY2018, amounting to $17.4 million [5] - The company anticipates U S revenue to grow to $94M to $98M in FY2019, a 12% to 17% increase [61] - The company is aiming for $200M in revenue in 2022 [17, 62] Strategic Initiatives - ATEC is shifting its focus towards organic innovation to drive double-digit growth [8, 12] - The company launched 12 new products in 2019 to create clinical distinction [22, 31, 33, 35] - ATEC aims to increase the percentage of revenue from products developed by the new ATEC team from less than 10% in 2018 to over 80% by 2022 [39] - The company is revitalizing its sales channel, aiming to increase revenue per distributor from $1 million to over $4 million [42, 49] Investments - R&D expenses increased by 104% from FY2017 to FY2018, reaching $10 million [58] - The company secured $30 million in new capital to support product development, marketing, and sales channel initiatives [60]